Abstract
CD133+ cells in glioblastoma (GBM) display cancer stem cell-like properties and have been considered as the culprit of tumor recurrence, justifying exploration of potential therapeutic modalities targeting CD133+ cancer stem-like cells (CSCs). For photothermolysis studies, GBM-CD133+ and GBM-CD133- cells mixed with various ratios were challenged with single-walled carbon nanotubes (SWNTs) conjugated with CD133 monoclonal antibody (anti-CD133) and then irradiated with near-infrared laser light. Results show that GBM-CD133+ cells were selectively targeted and eradicated, whereas GBM-CD133- cells remained viable. In addition, in vitro tumorigenic and self-renewal capability of GBM-CD133+ treated with localized hyperthermia was significantly blocked. Furthermore, GBM-CD133+ cells pretreated with anti-CD133-SWNTs and irradiated by near-infrared laser 2 days after xenotransplantation in nude mice did not exhibit sustainability of CSC features for tumor growth. Taken altogether, our studies demonstrated that anti-CD133-SWNTs have the potential to be utilized as a thermal-coupling agent to effectively target and destroy GBM CSCs in vitro and in vivo. From the Clinical Editor: Glioblastoma remains one of the most notorious cancer from the standpoint of recurrence and overall resistance to therapy. CD133+ stem cells occur among GBM cells, and may be responsible for the huge recurrence risk. This paper discusses a targeted elimination method of these cells, which may enable more efficient therapy in an effort to minimize or prevent recurrence. © 2011 Elsevier Inc.
Author supplied keywords
Cite
CITATION STYLE
Wang, C. H., Chiou, S. H., Chou, C. P., Chen, Y. C., Huang, Y. J., & Peng, C. A. (2011). Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine: Nanotechnology, Biology, and Medicine, 7(1), 69–79. https://doi.org/10.1016/j.nano.2010.06.010
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.